Pilot Study of BC-819/PEI and BCG in Patients With Superficial Transitional Cell Bladder Carcinoma

NCT01878188 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

38

Enrollment

INDUSTRY

Sponsor class

Conditions

Transitional Cell Carcinoma of Bladder

Interventions

DRUG: BC-819/PEI
DRUG: BCG Vaccine

Sponsor

Anchiano Therapeutics Israel Ltd.